NCT07609667Not yet recruitingPhase 2
A Phase II Study Evaluating the Efficacy and Safety of SKB315 Combination Therapy in Claudin18.2 Positive Patients With Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1 site in 1 country80 target enrollmentStarted: June 30, 2026Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Enrollment
- 80
- Locations
- 1
Study Overview
Brief Summary
This study is a multicenter,open-label,randomized, phase II clinical study conducted in China. The purpose of this study is to evaluate the efficacy of SKB315 plus PD-1 inhibitor ±capecitabine in patients with Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Detailed Description
This study is a multicenter,open-label,randomized, phase II clinical study conducted in China. The purpose of this study is to evaluate the efficacy of SKB315 plus PD-1 inhibitor ±capecitabine in patients with Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study will also evaluate efficacy, physical function, safety, and tolerability of SKB315 combination, as well as Pharmacokinetics (PK) of SKB315 and the immunogenicity profile of SKB315 will be evaluated as well.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Locally advanced unresectable or metastatic gastric cancer (GC) or gastroesophageal junction (GEJ) carcinoma and have histologically confirmed adenocarcinoma
- •No previous systemic therapy for locally advanced unresectable or metastatic gastric/GEJ cancer.
- •Consent to provide archival or fresh tumor tissue slides for immunohistochemistry (IHC) assessment, and advanced solid tumors with Claudin 18.2 and PD-L1 expression as determined by IHC;
- •Presence of at least one measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;
- •Eastern Cooperative Oncology Group (ECOG) score of 0 or 1;
- •Estimated survival ≥ 3 months as judged by the investigator;
- •Adequate organ and bone marrow function (no blood components and cytokines are allowed within 2 weeks prior to the first dose) ;
- •Patients of childbearing potential (male or female) must use effective medical contraception during the study and for 6 months after the end of dosing;
Exclusion Criteria
- •Active leptomeningeal disease or uncontrolled brain metastasis
- •Diagnosed with gastric or GEJ adenocarcinoma with positive HER2
- •Received other drugs in clinical study, major surgeries, or any other antitumor therapies within 4 weeks prior to the first dose of study treatment;
- •Patients with active hepatitis B or hepatitis C;
- •Patients have significant gastric bleeding
- •The presence of clinically uncontrollable third interspace fluid
- •Have clinically significant systemic diseases that may adversely affect the safety of the study;
- •Patients who may have poor compliance with the clinical study or have other factors based on which the investigator considers that the patients are not appropriate to patients in the study.
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT07489716Suzhou Suncadia Biopharmaceuticals Co., Ltd.90
Not yet recruiting
Phase 2
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerNCT07283198Jiangsu Alphamab Biopharmaceuticals Co., Ltd160
Recruiting
Phase 2
NWRD06 DNA Plasmid for HCC After Curative Resection.NCT07324304Newish Technology (Beijing) Co., Ltd.30
Not yet recruiting
Phase 2
Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological MalignanciesNCT07311538BioRay Pharmaceutical Co., Ltd.56
Not yet recruiting
Phase 2
Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical ProstatectomyProstate CancerNCT07415135Zhu Yinjie18